Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Maria Norrby; Daner Li; David A. Hokey; Ingrid Kromann; Søren T. Hoff; Peter Andersen; Adriëtte W. de Visser; Simone A. Joosten; Tom H. Ottenhoff; Jan Andersson; Susanna Brighenti; Timo Vesikari; Lars Lindqvist; Markus Maeurer; Raija Ahmed; Shahnaz Mahdavifar; Sean Bennett; J. Bruce McClain; Barbara M. Shepherd

doi:10.1016/j.vaccine.2017.01.055

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Maria Norrby, Daner Li, David A. Hokey, Ingrid Kromann, Søren T. Hoff, Peter Andersen, Adriëtte W. de Visser, Simone A. Joosten, Tom H. Ottenhoff, Jan Andersson, Susanna Brighenti, Timo Vesikari, Lars Lindqvist, Markus Maeurer, Raija Ahmed, Shahnaz Mahdavifar, Sean Bennett, J. Bruce McClain, Barbara M. Shepherd

Research output: Contribution to journal › Article › Scientific › peer-review

24 Citations (Scopus)

Original language	English
Pages (from-to)	1652-1661
Journal	VACCINE
Volume	35
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2017.01.055
Publication status	Published - 2017
Publication type	A1 Journal article-refereed

Keywords

Tuberculosis
clinical trial
human
immunity
safety
vaccine

Publication forum classification

Publication forum level 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2017.01.055

http://urn.fi/URN:NBN:fi:uta-201704111432

Cite this

Norrby, M., Li, D., Hokey, D. A., Kromann, I., Hoff, S. T., Andersen, P., de Visser, A. W., Joosten, S. A., Ottenhoff, T. H., Andersson, J., Brighenti, S., Vesikari, T., Lindqvist, L., Maeurer, M., Ahmed, R., Mahdavifar, S., Bennett, S., McClain, J. B., & Shepherd, B. M. (2017). Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. VACCINE, 35(12), 1652-1661. https://doi.org/10.1016/j.vaccine.2017.01.055

@article{d3d1a8c3cd224cca83c9f7796cb81bf1,

title = "Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials",

keywords = "Tuberculosis, clinical trial, human, immunity, safety, vaccine, Tuberculosis, clinical trial, human, immunity, safety, vaccine",

author = "Maria Norrby and Daner Li and Hokey, {David A.} and Ingrid Kromann and Hoff, {S{\o}ren T.} and Peter Andersen and {de Visser}, {Adri{\"e}tte W.} and Joosten, {Simone A.} and Ottenhoff, {Tom H.} and Jan Andersson and Susanna Brighenti and Timo Vesikari and Lars Lindqvist and Markus Maeurer and Raija Ahmed and Shahnaz Mahdavifar and Sean Bennett and McClain, {J. Bruce} and Shepherd, {Barbara M.}",

year = "2017",

doi = "10.1016/j.vaccine.2017.01.055",

language = "English",

volume = "35",

pages = "1652--1661",

journal = "VACCINE",

issn = "0264-410X",

publisher = "Elsevier",

number = "12",

}

Norrby, M, Li, D, Hokey, DA, Kromann, I, Hoff, ST, Andersen, P, de Visser, AW, Joosten, SA, Ottenhoff, TH, Andersson, J, Brighenti, S, Vesikari, T, Lindqvist, L, Maeurer, M, Ahmed, R, Mahdavifar, S, Bennett, S, McClain, JB & Shepherd, BM 2017, 'Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials', VACCINE, vol. 35, no. 12, pp. 1652-1661. https://doi.org/10.1016/j.vaccine.2017.01.055

TY - JOUR

T1 - Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

AU - Norrby, Maria

AU - Li, Daner

AU - Hokey, David A.

AU - Kromann, Ingrid

AU - Hoff, Søren T.

AU - Andersen, Peter

AU - de Visser, Adriëtte W.

AU - Joosten, Simone A.

AU - Ottenhoff, Tom H.

AU - Andersson, Jan

AU - Brighenti, Susanna

AU - Vesikari, Timo

AU - Lindqvist, Lars

AU - Maeurer, Markus

AU - Ahmed, Raija

AU - Mahdavifar, Shahnaz

AU - Bennett, Sean

AU - McClain, J. Bruce

AU - Shepherd, Barbara M.

PY - 2017

Y1 - 2017

KW - Tuberculosis

KW - clinical trial

KW - human

KW - immunity

KW - safety

KW - vaccine

KW - Tuberculosis

KW - clinical trial

KW - human

KW - immunity

KW - safety

KW - vaccine

U2 - 10.1016/j.vaccine.2017.01.055

DO - 10.1016/j.vaccine.2017.01.055

M3 - Article

SN - 0264-410X

VL - 35

SP - 1652

EP - 1661

JO - VACCINE

JF - VACCINE

IS - 12

ER -